INTRODUCTION
Perianal fistulas can develop to up to one-third of patients with Crohn's disease (CD) leading to disabling disease, morbidity, and a significant impairment in quality of life [1] . The treatment of fistulising perianal CD is not simple and often requires a multidisciplinary approach of both pharmacological and surgical therapy especially for complex perianal fistulae [2] .
anti-tumor necrosis factor (anti-TNF) therapy has revolutionized the treatment of both perianal and internal fistulising CD [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Nevertheless, therapeutic outcomes from randomised controlled trials (RCTs), post-hoc analyses of RCTs and real-life prospective or retrospective studies show that long-term remission can be achieved in only 30%-50% of patients (Table  1) . Moreover, these percentages refer mostly to clinical remission, based on symptoms and physician global assessment (PGa), and not to objective endoscopic and/or radiological healing. at this time, the preferred goal of treatment should be deep remission, or the combination of clinical and the more objective measures, including radiologic and endoscopic healing. as therapeutic options for perianal fistulising CD are still limited it is very important to attempt to predict and subsequently prevent treatment failure in these patients. Preliminary data demonstrate that higher infliximab concentrations are associated with improved clinical outcomes in patients with perianal fistulising CD, suggesting that therapeutic drug monitoring (TDM) and a treat-to-trough approach is likely a valid therapeutic strategy for optimizing anti-TNF therapy in these patients [19, 20] .
Defining deep remission
Most studies typically use clinical remission, defined as absence of any draining fistulas based on PGA and patients' reports, as a therapeutic endpoint for perianal fistulising CD [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Nevertheless, deep remission, defined as mucosal and/or radiological healing of fistulas, is likely a more appropriate goal of therapy for perianal fistulising CD. T2-weighted magnetic resonance imaging (MRI) with fat-suppression is considered the goldstandard for fistula imaging and an MRI-based score is currently available for defining disease activity, although it is still not widely used in clinical practice [1] . Thomassin et al [11] have recently showed that deep remission, defined as a composite clinical (absence of any draining fistulas and self-reported drainage episodes by the patient at two successive evaluations), endoscopic (absence of ulcers in the anal canal) and radiological (absence of T2 hyperintensity and contrast enhancement on MRI) remission, was achieved in approximately onethird of patients with perianal fistulizing CD [11] .
Predicting deep remission
As new drugs for the treatment of perianal fistulising CD are still awaited, it is important to be able to predict who will achieve deep remission and who will not respond adequately to typical anti-TNF dosing and will require early (and continued) optimization [1, 2] . although several variables have been associated with improved outcomes (Table 2) , prediction of deep remission remains a challenge. Thomassin et al [11] have recently identified absence of rectal involvement on MRI (OR = 4.6; 95%CI: 1.03-20.5) as the only variable associated with deep remission in patients with perianal fistulizing CD [11] . Similar to ulcerative colitis and luminal CD [19] [20] [21] [22] [23] [24] [25] , recent data demonstrate that higher infliximab concentrations are associated with better clinical outcomes in patients with perianal fistulising CD [26, 27] . Regarding maintenance therapy Yarur et al [26] recently showed that infliximab trough concentrations ≥ 10.1 μg/mL are associated with fistula healing and based on quartile analyses proposed that physicians should aim for even higher concentrations (> 20.2 μg/mL) before giving up and moving on to alternative therapies with a different mechanism of action.
CONCLUSION
Deep remission defined as a composite clinical, endoscopic and radiological remission should really be considered the goal of therapy in patients with perianal fistulizing CD. TDM may be a valid therapeutic strategy for optimising anti-TNF therapy, improving therapeutic outcomes, and moving towards more personalized medical care. Absence of active proctitis [11] TNF: Tumor necrosis factor; MRI: Magnetic resonance imaging.
